Bracco Diagnostics Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.0M | 264 | 41.3% |
| Grant | $1.4M | 33 | 18.9% |
| Consulting Fee | $1.0M | 213 | 14.5% |
| Royalty or License | $925,664 | 50 | 12.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $331,183 | 30 | 4.6% |
| Honoraria | $291,415 | 104 | 4.0% |
| Travel and Lodging | $143,541 | 191 | 2.0% |
| Food and Beverage | $82,789 | 1,233 | 1.1% |
| Education | $22,418 | 5 | 0.3% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $18,000 | 6 | 0.2% |
| Charitable Contribution | $9,960 | 3 | 0.1% |
| Entertainment | $1,113 | 13 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $428.60 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| THE SAFETY AND EFFICACY OF PROHANCE AT THE DOSE OF 0.10 MMOL/KG IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PATIENTS WHO ARE YOUNGER THAN 2 YEARS OF AGE | $257,736 | 0 | 19 |
| IMPACT OF CORONARY ARTERY STENTING ON QUANTITATIVE MYOCARDIAL BLOOD FLOW AND HEALTH STATUS | $251,095 | 1 | 4 |
| A PARALLEL-GOUP COMPARISON OF TWO DOSES OF MULTIHANCE (0.10 MMOL/KG AND 0.05 MMOL/KG) WHEN USED FOR MAGNETIC RESONANCE IMAGING (MRI) OF THE CENTRAL NERVOUS SYSTEM (CNS) | $216,028 | 2 | 11 |
| AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED A GADOLINIUM-BASED CONTRAST AGENT (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE) | $211,377 | 2 | 21 |
| AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED A GADOLINIUM-BASED CONTRAST AGENT (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE) | $179,490 | 0 | 2 |
| Added value of gadopiclenol-enhanced MR imaging compared to noncontrast MR imaging in Crohns disease. | $178,426 | 0 | 6 |
| A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery Disease | $140,328 | 7 | 19 |
| A PROSPECTIVE MULTICENTER PHASE III CLINICAL EVALUATION OF THE SAFETY AND EFFICACY OF LUMASON/SONOVUE IN SUBJECTS UNDERGOING PHARMACOLOGIC STRESS ECHOCARDIOGRAPHY WITH DOBUTAMINE FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE | $124,630 | 1 | 19 |
| THE IMPACT OF CORONARY REVASCULARIZATION ON ABSOLUTE MYOCARDIAL BLOOD FLOW AS ASSESSED BY STRESS MYOCARDIAL POSITRON EMISSION TOMOGRAPHY | $113,540 | 0 | 3 |
| IIS-US-0145 | $110,000 | 0 | 1 |
| Diagnostic Utility of MRI in Female Patients with Nipple Discharge: A Prospective Trial | $104,238 | 0 | 4 |
| A PROSPECTIVE, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE THYROID FUNCTION OF PEDIATRIC SUBJECTS FROM BIRTH TO 3 YEARS EXPOSED TO ISOVUE (IOPAMIDOL INJECTION) | $102,334 | 1 | 12 |
| An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Received a Gadolinium-Based Contrast Agent (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE) | $93,785 | 0 | 22 |
| Comparison of MBF and CFR measurements as calculated by HeartSee, using PET MPI data obtained with Rb-82 infused at 50 vs. 20 mL/min using the CardioGen-82 Model 1700 Infusion System | $88,065 | 0 | 1 |
| INCREASING SPATIAL RESOLUTION OF CONTRAST-ENHANCED MR ANGIOGRAPHY:UTILIZING OPTIMIZED INJECTION PROFILES | $81,382 | 1 | 2 |
| Capability of Artificial Intelligence to Detect Malignancy in Low Dose Breast MRI | $70,000 | 0 | 3 |
| INCIDENCE OF NEPHROGENIC SYSTEMIC FIBROSIS (NSF) IN PATIENTS WITH LOW EGFR RECEIVING GADOTERIDOL (PROHANCE) FOR CONTRAST-ENHANCED MRI | $62,072 | 0 | 4 |
| A PROSPECTIVE MULTICENTER COHORT STUDY EVALUATING THE LONG TERM RETENTION OF GADOLINIUM IN HUMAN BONE AND SKIN AFTER THE RETROSPECTIVE ADMINISTRATION OF MULTIHANCE OR PROHANCE IN COMPARISON WITH A CONTROL GROUP RECEIVING NO EXPOSURE TO GADOLINIUM | $52,773 | 0 | 6 |
| Lumason Bolus vs Infusion | $49,993 | 0 | 2 |
| IIS-US-106 | $40,691 | 0 | 1 |
| A Prospective Multicenter Cohort Study Evaluating The Long Term Retention of Gadolinium In Human Bone and Skin After The Retrospective Administration of Multihance or Prohance in Comparison With a Control Group Receiving No Exposure to Gadolinium | $34,442 | 0 | 1 |
| A MULTICENTER CLINICAL EVALUATION OF SAFETY AND EFFICACY OF SONOVUE AS A CONTRAST AGENT IN PEDIATRIC ECHOCARDIOGRAPHY | $30,536 | 0 | 4 |
| EVALUATION OF REGIONAL GADOLINIUM RETENTION IN THE BRAIN USING QSM WITH CORRELATION TO REGIONAL DCE MRI PERMEABILITY USING GOCART TECHNIQUE IN INTRACRANIAL NEOPLASM PATIENTS RECEIVING GADOBENATE DIMEGLUMINE (MULTIHANCE) AND GADOTERATE MEGLUMINE (DOTAREM) | $30,000 | 0 | 1 |
| Wang Jin-Intraindividual comparison of MultiHance at the dose of 0.05 mmol/kg and Primovist at the dose of 0.025 mmol/kg in terms of diagnostic performance for detection of hepatocellular carcinoma (HCC) nodules | $25,000 | 1 | 1 |
| Screening Breast MRI with Gadopiclenol | $25,000 | 0 | 1 |
| IMPACT OF GENDER, BODY MASS INDEX AND BREAST CUP SIZE ON THE CORRELATION BETWEEN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY AND CORONARY ANGIOGRAPHY | $22,230 | 0 | 1 |
| Bober_The Impact of Absolute Resting Myocardial Flow and Coronary Flow Reserve on Left Ventricular Geometries, Renal Function and Death | $22,230 | 0 | 1 |
| A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue | $19,250 | 0 | 8 |
| Comparison of MBF and CFR measurements as calculated by HeartSee, using PET MPI data obtained with Rb-82 infused at 50 vs. 20 mL/min using the CardioGen-82 Model 1700 Infusion System. | $17,613 | 0 | 1 |
| PROSPECTIVE EVALUATION OF LONG-TERM EFFECTS OF REPEATED GADOLINIUM-BASED CONTRAST AGENT (GBCA) ADMINISTRATIONS OF THE SAME GBCA ON MOTOR AND COGNITIVE FUNCTIONS IN NEUROLOGICALLY NORMAL ADULTS IN COMPARISON TO A NON-EXPOSED CONTROL GROUP. | $16,333 | 1 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Steven Feinstein, M.d, M.D | Cardiovascular Disease | Chicago, IL | $7,942 | $0 |
| Rupan Sanyal, Md, MD | Diagnostic Radiology | Jacksonville, FL | $7,878 | $0 |
| Dr. Christopher Comstock, M.d, M.D | Diagnostic Radiology | San Diego, CA | $6,587 | $0 |
| Dr. Ryan Lee, Md, MD | Diagnostic Radiology | Philadelphia, PA | $6,488 | $0 |
| Scott Reeder, Md Phd, MD PHD | Diagnostic Radiology | Madison, WI | $6,182 | $0 |
| John Finn, Md, MD | Diagnostic Radiology | Los Angeles, CA | $6,130 | $0 |
| Dr. Diego Martin, M.d,Phd, M.D,PHD | Diagnostic Radiology | Atlanta, GA | $5,842 | $0 |
| Sanjiv Kaul, Md, MD | Cardiovascular Disease | Portland, OR | $5,772 | $0 |
| Sanjay Saini, Md, MD | Diagnostic Radiology | Boston, MA | $5,745 | $0 |
| Dr. Edward Miller, Md, Phd, MD, PHD | Cardiovascular Disease | New Haven, CT | $5,681 | $0 |
| Richard Semelka, Md, MD | Body Imaging | Iowa City, IA | $5,484 | $0 |
| Dr. Max Wintermark, Md, MD | Diagnostic Radiology | Houston, TX | $5,422 | $0 |
| Andrej Lyshchik, M.d., Ph.d, M.D., PH.D | Vascular & Interventional Radiology | Philadelphia, PA | $5,421 | $0 |
| David Rosman, M.d, M.D | Diagnostic Radiology | Burlington, MA | $5,100 | $0 |
| Jonathan Lindner, Md, MD | Internal Medicine | Charlottesville, VA | $5,000 | $0 |
| Jessica Zarzour | Diagnostic Radiology | Birmingham, AL | $5,000 | $0 |
| Dr. Jerry Froelich, M.d, M.D | Nuclear Medicine | Minneapolis, MN | $4,949 | $0 |
| Jeong Mi Park | Diagnostic Radiology | Birmingham, AL | $4,769 | $0 |
| Elizabeth Morris, Md, MD | Diagnostic Radiology | New York, NY | $4,483 | $0 |
| Dr. Jorge Soto, Md, MD | Diagnostic Radiology | Boston, MA | $4,447 | $0 |
| David Francis, Md Ms, MD MS | Otolaryngology | Madison, WI | $4,058 | $0 |
| Shreyas Vasanawala, Md, MD | Diagnostic Radiology | Palo Alto, CA | $4,000 | $0 |
| Amelie Lutz, Md, MD | Diagnostic Radiology | Stanford, CA | $4,000 | $0 |
| Dr. Nicholas Matthees, M.d, M.D | Diagnostic Radiology | Phoenix, AZ | $3,944 | $0 |
| Amish Doshi, M.d, M.D | Diagnostic Radiology | New York, NY | $3,822 | $0 |
Top Products
- ISOVUE $2.5M
- Cardiogen-82 $650,678
Associated Products (28)
- ISOVUE $2.6M
- Cardiogen-82 $650,678
- MULTIHANCE $592,864
- PROHANCE $461,716
- Lumason $372,534
- LUMASON $354,487
- MultiHance $340,659
- ProHance $340,317
- Isovue $299,295
- Vueway (gadopiclenol) $201,673
- CARDIOGEN $146,115
- MRI $107,737
- MR (Group) $96,406
- Multihance $91,701
- SONOVUE $71,360
- VARIBAR THIN LIQUID $58,446
- CARDIOGEN-82 $43,556
- VUEWAY $42,501
- GMRA INVESTIGATIONS $36,619
- CardioGen $36,127
- Protoco2L $27,500
- Barium $22,965
- MRI INVESTIGATIONS $21,029
- Varibar $18,000
- Nexo $15,134
- GMRA INVESTIGATION $14,438
- CEUS $14,414
- VARIBAR $10,000
Payment Categories
- Food & Beverage $82,789
- Consulting $1.0M
- Travel & Lodging $143,541
- Research $3.0M
- Royalties $925,664
About Bracco Diagnostics Inc.
Bracco Diagnostics Inc. has made $7.2M in payments to 892 healthcare providers, recorded across 2,146 transactions in the CMS Open Payments database. In 2024, the company paid $834,612. The top product by payment volume is ISOVUE ($2.5M).
Payments were distributed across 55 medical specialties. The top specialty by payment amount is Diagnostic Radiology ($1.5M to 225 doctors).
Payment categories include: Food & Beverage ($82,789), Consulting ($1.0M), Research ($3.0M), Travel & Lodging ($143,541), Royalties ($925,664).
Bracco Diagnostics Inc. is associated with 28 products in the CMS Open Payments database, including ISOVUE, Cardiogen-82, and MULTIHANCE.